Dianthus Therapeutics, Inc. entered into a securities purchase agreement with certain institutional and accredited investors 14,500,500 common shares at an issue price of $12 per share for gross proceeds of $174,006,000 and pre-funded warrants to purchase up to 4,666,332 shares of common stock at an issue price of $11.999 per pre-funded warrant for gross proceeds of $55,991,317.668 resulting aggregate gross proceeds of $229,997,317.668 on January 22, 2024. The transaction will include participation from new and existing investors, including Bain Capital Life Sciences, RA Capital Management, Avidity Partners, Fairmount, Venrock Healthcare Capital Partners, RTW Investments, Great Point Partners LLC, Octagon Capital, Janus Henderson Investors, Vestal Point Capital, Logos Capital, Catalio Capital Management, Woodline Partners LP, Ally Bridge Group, Tellus BioVentures, StemPoint Capital LP and a large investment management firm. The transaction is expected to close on January 24, 2024.